abbvie glp-1 receptor agonists weight management diabetes treatments Advances in delivery systems for obesity and abbvie glp-1 receptor agonists weight

A recently-published investigatory review reports nine people taking semaglutide and tirzepatide experienced vision issues

They boost insulin secretion in response to glucose while inhibiting glucagon release, aiding in blood sugar control without causing hypoglycemia

Bremholm L, Andersen UB, Hornum M, Hilsted L, Veedfald S, Hartmann B, et al

If additional glycemic control is needed, the dose can be increased in 2.5-mg increments every 4 weeks to a maximum of 15 mg once weekly

Adverse drug reactions currently account for an estimated 2.2 billion in NHS hospital stays annually, and one in six hospital admissions is linked to medication-related harm

The study period on medication or placebo following the lifestyle intervention is 72 weeks (84)